secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001641172-25-001486
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric Biosciences Q4 2024 net loss $3.2M, cash $2.2M; out-licenses up to $144M
--------------------------------------------------------------------------------

- Net loss $3.2M for Q4 2024; diluted EPS loss $4.83; cash-on-hand $2.2M.
- Out-licensing deals with Aries ($61M milestones), MycoMedica ($62M), Restoration Biologics ($82M).
- Lead candidate EB-003 confirmed oral bioavailability and brain exposure; pre-IND activities ongoing.
- Closed $5M public offering in 2024 to fund development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000164117225001486/0001641172-25-001486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000164117225001486/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-001486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer